AUTHORS
Sifan Chen, Suning Chen2, Haiping Dai3, Depei Wu Sr, MD4
AFFILIATIONS
1 the First Affiliated Hospital of Soochow University, Suzhou, China
2 the First Affiliated Hospital of Soochow University, Suzhou, China
3 the First Affiliated Hospital of Soochow University, Suzhou, China
4 the First Affiliated Hospital of Soochow University, Suzhou, China
ABSTRACT
Background
Acute myeloid leukemia (AML) with KMT2A rearrangement (KMT2Ar) is classified as intermediate- or adverse-risk disease, characterized by intrinsic chemoresistance and poor long-term outcomes with conventional intensive chemotherapy (IC). Leukemic cells harboring KMT2Ar display inherent epigenetic susceptibility to BCL-2 inhibition, and indeed, KMT2Ar AML has shown high remission rates with low-intensity therapy consisting of venetoclax plus hypomethylating agents (VEN+HMA). However, comparative studies directly contrasting IC and VEN+HMA in terms of remission rate, depth and duration, as well as their efficacy as a bridge to allogeneic stem cell transplantation, remain scarce.
Methods
A total of 119 newly diagnosed patients with KMT2Ar AML who received treatment at our center and referring institutions between Feb, 2020 and Nov, 2025 were enrolled in this retrospective study. Among them, 54 patients were treated with VEN+HMA as induction therapy, and 65 received IC. Flow cytometry-based measurable residual disease (MRD) negativity (<0.1%) and complete molecular remission (CMR; defined as transcript levels below the limit of detection via RT-qPCR) were dynamically monitored. Treatment responses were assessed in accordance with ELN 2022. The cumulative incidence of relapse (CIR) and non-relapse mortality (NRM) between the two cohorts were compared using the Fine-Gray competing risks model.
Results
Baseline patient characteristics were well balanced between the two treatment groups. After the first cycle of induction therapy (C1), the ORR was comparable in patients treated with VEN+HMA versus IC (64.8% vs. 56.9%). However, subgroup analyses revealed significantly higher ORRs with VEN+HMA in patients harboring the KMT2A::AFDN fusion (100% vs. 44.4% with IC, P=0.046) and KMT2A::ELL fusion (92.9% vs. 55.6% with IC, P=0.044).
VEN+HMA was also associated with a higher proportion of flow cytometry-detected MRD negativity in the overall cohort (51.9% vs. 40.0% with IC) and, notably, in KMT2A::ELL-positive patients (78.6% vs. 33.3% with IC, P=0.016). Additionally, VEN+HMA improved the 6-month CMR rate compared with IC (75.3% vs. 58.1%). Multivariate logistic regression analysis identified concurrent KRAS mutation as an independent predictor of lower CMR achievement post-C1 (adjusted odds ratio=5.44, P=0.046). Among IC-refractory patients, salvage therapy with VEN+HMA resulted in a 75% CMR rate. With respect to safety, VEN+HMA was associated with a significant reduction in early severe infections compared with IC (66.7% vs. 91.2%, P=0.027).
In the overall cohort, VEN+HMA was associated with a slightly inferior 2-year OS rate versus IC (72.0% vs. 88.0%, P=0.022), while 2-year EFS rates were comparable (32.2% vs. 41.8%, P=0.46). Among patients who achieved remission, 2-year CIR was similar between groups (43.6% vs. 46.2%, P=0.998). Patients who received VEN+HMA induction followed by allo-HSCT had a 2-year OS rate of 81.4%. Among patients undergoing allo-HSCT in first complete remission, those treated with VEN+HMA induction showed a numerically lower 2-year CIR compared with IC (18.2% vs. 31.6%, P=0.471). Multivariable Cox regression analysis identified allo-HSCT as the primary protective factor for OS (hazard ratio=0.09, P<0.001), and the KMT2A::ELL variant as a strong protective factor for EFS (hazard ratio=0.41, P=0.036). Regarding pre-HSCT MRD dynamics, 83.3% of patients who received VEN+HMA induction followed by allo-HSCT achieved pre-transplant MRD negativity. Conclusion
In conclusion, VEN+HMA induction demonstrates comparable overall efficacy to IC in KMT2Ar AML, with distinct superiority in those harboring KMT2A::AFDN or KMT2A::ELL fusions. VEN+HMA also improves response depth, reduces early severe infections, and shows promising salvage efficacy in IC-refractory patients. VEN+HMA induction and post-remission allo-HSCT yield excellent long-term outcomes.
DISCLOSURES
Sifan Chen: No relevant conflicts of interest to declare.